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The bactericidal activity of gatifloxacin, alone and in combination with isoniazid and rifampin, was studied
on both exponential- and stationary-phase cultures of Mycobacterium tuberculosis strain H37Rv. On log-phase
cultures, the bactericidal activity of gatifloxacin at 4 g/ml was rapid and was very similar to that of isoniazid.
At concentrations of 0.25 and 4 g/ml, gatifloxacin enhanced the activity of isoniazid. Killing of the stationary-
phase culture was biphasic. During the first 2 days, gatifloxacin at 4 g/ml slightly increased the limited
bactericidal activities of isoniazid and rifampin. However, no further additional bactericidal activity was found
during further incubation with isoniazid alone or when gatifloxacin was added to either isoniazid or rifampin.
This suggested that the stationary-phase culture contained a mixture of occasionally dividing bacilli that were
killed during the first 2 days and true static persisters in the residual population that mimicked those in
human lesions. In view of the failure of gatifloxacin to add to the sterilizing activity of isoniazid or rifampin
during days 2 to 6 of exposure in the stationary-phase culture, it is unlikely to be a sterilizing drug that can
be used to shorten the duration of treatment appreciably when it is added to present treatment regimens.
Tuberculosis continues to be one of the leading causes of
death in the world. Although directly observed treatment,
short course (DOTS), contributes to the control of the disease,
noncompliance with treatment continues to be the main cause
of poor results. Even in places where the DOTS strategy is
reported to be a success, the main reason cited for noncom-
pliance is the long, 6-month duration of treatment (17). Hence,
shortening of the duration of treatment without compromising
the cure and relapse rates still remains a major goal for control
policies. Evidence that the addition of fluoroquinolones to
present treatment regimens might shorten their duration has
been provided by studies of experimental murine tuberculosis
(14) and by a clinical trial at the Tuberculosis Research Centre,
Chennai, India (16). Further clinical trials of fluoroquinolones
aimed at shortening treatment, with backing in the United
States (14) and from the European Commission (10), are pro-
ceeding. Among the fluoroquinolones, those with the greatest
activity in tuberculosis are ofloxacin (OFX), levofloxacin,
which should act in the same manner, and the newer quino-
lones such as 8-methoxy derivatives gatifloxacin (GAT) and
moxifloxacin. In vitro studies have compared the in vitro bac-
tericidal actions of each of these four quinolones and suggest
that among the fluoroquinolones GAT and moxifloxacin have
the greatest activities, even though they are still limited,
against static bacterial populations of Mycobacterium tubercu-
losis that might resemble those in human lesions (5).
During the initial phase of chemotherapy, which lasts for
about 2 days, bacilli are killed exponentially at a rapid rate,
followed by a further lengthy period of much slower exponen-
tial killing (7). It is assumed that the bacilli killed in the first 2
days are actively multiplying, while those in the succeeding
period are persisters killed by the slower sterilizing activities of
the drugs. Drugs differ in their relative bactericidal activities
during the initial 2 days, when the activity of isoniazid (INH)
predominates, and in their subsequent sterilizing activity, when
the activity of rifampin (RIF) predominates (2, 7). An in vitro
model of drug action, a 30-day static culture, has been exten-
sively used since 1956 and has been taken to resemble the
persister population in its response to drugs (4, 11, 12). The
drugs added have the same slow sterilizing action that is re-
sponsible for the prolongation of therapy. We compared the
activity of GAT, with and without other antituberculosis drugs,
on an actively growing log-phase, 2- to 6-day-old culture with
that on a static, 30-day culture.
MATERIALS AND METHODS
Test drugs. INH, RIF, and OFX were purchased from Sigma Chemical Co.
(St. Louis, Mo.) and GAT was kindly provided by Dr. Reddy’s Laboratory Ltd.
(Hyderabad, India). Stock solutions of OFX and GAT were prepared in 0.1 N
NaOH, stock solutions of INH were prepared in sterile distilled water, and stock
solutions of RIF were prepared in dimethyl formamide. The stock solutions were
sterilized by filtration through cellulose membranes with a pore size of 0.22 m,
and further dilutions were then made in sterile distilled water. INH and RIF
were tested at final concentrations of 1 g/ml, OFX was tested at a final con-
centration of 2 g/ml, and GAT was tested at final concentrations of 0.25 g/ml
(GAT1) and 4 g/ml (GAT2).
Exponential-phase and stationary-phase cultures of M. tuberculosis. M. tuber-
culosis strain H37Rv was grown in 10 ml of 7H9 medium with Tween 80–
albumin–dextrose for 7 days at 37°C. The total number of bacilli per milliliter in
this growth medium was determined with a Thoma counting chamber. Two
Erlenmeyer flasks, each of which contained 400 ml of fresh 7H9 culture medium,
were stoppered with paper-wrapped bungs to reduce the level of oxygen tension
but not to exclude it. The culture medium was then inoculated with an appro-
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priate volume of the 7-day culture to give a concentration of 105 bacilli per ml.
One of the flasks was incubated at 37°C for 3 days (log-phase culture), while the
other flask was incubated at 37°C for 4 weeks (stationary-phase culture), during
which time the flask was left undisturbed and growth continued under a 4- to
5-cm layer of medium (4).
Bactericidal actions of the drugs. The log-phase and stationary-phase cultures
of M. tuberculosis were distributed without dilution or concentration in 10-ml
aliquots into 28-ml screw-cap McCartney bottles (day 0). About 1 h later, the
drugs were added to duplicate aliquots of these cultures at the following final
concentrations: INH, 1 g/ml; RIF, 1 g/ml, OFX, 2 g/ml (4); GAT, 0.25 g/ml
(GAT1), the MIC for M. tuberculosis (15); and GAT, 4 g/ml (GAT2), the peak
concentration attainable in serum with the present dosage of 400 mg used for the
treatment of human disease (3). The two GAT concentrations were tested alone
and in combinations as INH-GAT, RIF-GAT, and INH-RIF-GAT. Drug-free
control cultures were included. On day 3 the drugs were replenished with 50% of
the original quantity for INH and RIF, 10% of the original quantity for OFX,
and 25% of the original quantity for GAT to compensate for the losses during
the 3 days of incubation, as estimated from standardization experiments (4). On
days 0, 2, 4, and 6, serial 10-fold dilutions of these cultures were inoculated on
duplicate plates of selective 7H11 agar medium (13) containing polymyxin B (200
U/ml), amphotericin B (20 g/ml), carbenicillin (100 g/ml), and trimethoprim
(10 g/ml) to determine CFU counts. The plates were placed in polyethylene
bags and incubated at 37°C. The colonies were counted after 2 and 4 weeks of
incubation (4).
Part of the experiment with log-phase cultures was repeated with CFU counts
determined at 2, 6, 12, 24, 36, 48, and 72 h, since no CFU was observed after 2
days in the presence of INH alone or INH in combination with GAT.
Statistics. The results were expressed as the mean of the duplicate experi-
ments at each time point. Differences in the regression coefficients of the log
CFU counts with different drug combinations were tested by analysis of variance
by using test command in Stata software (release 8; Stata Corp., College Station,
Tex.). The standard deviation of a result was obtained from the variation be-
tween the CFU counts for the duplicate cultures, estimated separately for the
log-phase and the stationary-phase cultures. Counts that yielded no colonies in
either of the duplicates were excluded.
Graphing. No adequate representation on a logarithmic axis of the CFU count
could be made for counts that yielded no colonies since log 0 is minus infinity. A
line was therefore drawn to extrapolate the values obtained at the two previous
time points, provided that it cut the x axis to the left of the time point that yielded
no colonies. Otherwise, the line was drawn through log 0. In each case, the line
concerned has been drawn dotted in Fig. 1 to 4 to indicate the uncertainty in its
true position. Counts after the first negative count always failed to yield colonies,
and their values have not been entered in the figures.
RESULTS
The results of the bactericidal activities of different drugs
from the two sets of experiments, one on the exponential-
phase culture and the other on the stationary-phase culture,
are given in successive figures, each of which describes the
different comparisons of individual drugs within the same ex-
periment. The standard deviation of a count was estimated to
be 0.125 log10 (on the basis of 13 degrees of freedom) with the
log-phase cultures and 0.126 log10 (on the basis of 44 degrees
of freedom) with the stationary-phase cultures.
Activities of individual drugs. The 6-day CFU counts from
the log-phase culture are shown in Fig. 1A, and those from the
stationary-phase cultures are shown in Fig. 1C, with the results
of the repeat 24-h experiment on the log-phase culture shown
in Fig. 1B. The drug-free controls showed, as expected, con-
tinuous growth in the log-phase culture but no increase in CFU
in the stationary-phase culture. In the log-phase culture, INH
was the most bactericidal, GAT2 was slightly less active, GAT1
and OFX were less active still, and RIF was the least active (P
 0.001). In the stationary-phase culture, RIF showed the
highest activity (P 0.001), with counts decreasing throughout
the experiment. During the first 2 days, GAT2 was the most
bactericidal, followed by INH, GAT1, and OFX (P  0.001).
FIG. 1. Bactericidal activities of INH at 1 g/ml, RIF at 1 g/ml,
OFX at 2 g/ml, GAT1 at 0.25 g/ml, and GAT2 at 4 g/ml (G2)
against exponential-phase (A), log-phase (B), and stationary-phase
(C) cultures of M. tuberculosis. H, INH; R, RIF; G1, GAT1; G2,
GAT2; and OF, OFX.
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However, none of these four drugs was bactericidal during the
succeeding 4 days. This suggests that the stationary-phase cul-
ture contained two bacterial populations: a majority popula-
tion (population A) of bacilli that had relatively high levels of
metabolism with occasional multiplication and the remaining
population (population B) of bacilli with truly static, low-level
metabolism.
Effect of addition of GAT to INH. The effect of combinations
of GAT with INH on the log-phase culture is shown in Fig. 2A.
GAT at both concentrations augmented the bactericidal activ-
ity of INH. Negative counts were obtained with GAT1-INH in
just over 6 h but were obtained with GAT2-INH in less than
3 h. With the stationary-phase culture (Fig. 2B), INH-GAT1 (P
 0.05) was more active than INH alone and GAT2-INH (P 
0.001) was slightly more bactericidal. However, bactericidal
activity with all three combinations occurred during the first 2
days and was not evident subsequently. The most bactericidal
combination was INH-RIF, whose activity continued even af-
ter day 2.
Effect of addition of GAT to RIF. With the log-phase culture
(Fig. 3A), combinations of GAT1 and GAT2 with RIF did not
increase the activity of RIF alone. Indeed, RIF appeared to
antagonize the bactericidal activity of GAT considerably, since
the counts were 4.50 log10 CFU/ml (P  0.001) with GAT1-
RIF and 4.24 log10 CFU/ml (P 0.001) with GAT2-RIF, while
negative counts were obtained at 4 days with both GAT1 and
GAT2 alone (Fig. 1A). INH-RIF was far more bactericidal.
With the stationary-phase culture (Fig. 3B), there again ap-
peared to be slight antagonism when GAT1 was added to RIF
and a marginal increase in activity during the first 2 days only
when GAT2 was added to RIF.
Effect of addition of GAT to INH and RIF. There is only a
suggestion (nonsignificant) that the addition of GAT1 and
GAT2 to INH-RIF slightly increased the bactericidal action on
the log-phase culture (Fig. 4A). With the stationary-phase cul-
ture (Fig. 4B), the addition of GAT1 to INH-RIF did not alter
the activity. The addition of GAT2 increased the activity dur-
ing the first 2 days (P  0.001), but no conclusion could be
drawn beyond 2 days, since negative cultures were obtained.
DISCUSSION
GAT was remarkably bactericidal against log-phase organ-
isms, second only to INH. When GAT was added to INH it
FIG. 2. Bactericidal activities of INH alone and INH with RIF or
GAT1 and GAT2 against log-phase (A) and stationary-phase (B) cul-
tures of M. tuberculosis. See Fig. 1 for drug concentrations. H, INH;
HG1, INH-GAT1; HG2, INH-GAT2; and HR, INH-RIF.
FIG. 3. Bactericidal activities of RIF alone and RIF with INH or
GAT1 and GAT2 against log-phase (A) and stationary-phase (B) cul-
tures of M. tuberculosis. See Fig. 1 for drug concentrations. R, RIF;
RG1, RIF-GAT1; RG2, RIF-GAT2; and HR, INH-RIF.
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greatly increased the bactericidal activity when it was added at
both the high concentration and the low concentration. How-
ever, RIF substantially inhibited the activities of GAT at both
concentrations (P  0.001). With the stationary-phase culture,
the effects during the first 2 days must be distinguished from
those during the next 4 days. During the first 2 days, INH was
slightly bactericidal, but it had no further bactericidal activity
during days 2 to 6. Since INH is a cell wall antagonist, these
findings suggest that the majority bacterial population (popu-
lation A) in the stationary culture was occasionally dividing
and was killed during the first 2 days, leaving a remainder
population (population B) insusceptible to INH because it was
no longer dividing. In contrast, RIF continued to kill the bacilli
during the entire 6-day period, although it did so more slowly
during days 4 to 6 (Fig. 1C). This suggests that the bacilli in
population A had higher metabolic rates than those in popu-
lation B, since the rate of killing by RIF was slowed by factors
that reduced bacillary metabolism. By considering first the
effects of GAT on population A during the first 2 days, GAT
increased the bactericidal activities of INH (P  0.001) (Fig.
2B) and RIF (P  0.001) (Fig. 3B). However, during the
succeeding 4 days, GAT was not bactericidal alone on popu-
lation B (Fig. 1C) and failed to demonstrate any such syner-
gistic action. It did not significantly alter the activity of INH
(Fig. 2B) or RIF (Fig. 3B), and no assessment during days 2 to
6 could be made when it was added to INH-RIF (Fig. 4B),
since negative cultures were obtained after day 2.
To what extent do these findings reflect on the probable
response of pulmonary tuberculosis to regimens that incorpo-
rate GAT? Are the responses to drugs of the bacilli in the
log-phase and the stationary-phase cultures similar to those of
bacilli in human lesions? The first study of early bactericidal
activity measured the changes in CFU counts of M. tuberculosis
in sputum during the treatment of patients with pulmonary
tuberculosis with 22 different combinations of INH, RIF, pyr-
azinamide, ethambutol, and streptomycin (8). A recent reanal-
ysis of the data showed that there was an initial 2-day period
when INH was the predominant drug that killed the bacilli at
the fastest rate of about log10 0.6 CFU/day and that the activity
of INH was unaffected by the other drugs in the regimen (7).
In contrast, regimens with RIF, but without INH, killed the
bacilli at a lower rate of about log10 0.3 CFU/day (7). Actively
growing organisms are thought to be killed during this initial
phase. These findings are in substantial agreement with our
findings on the log-phase culture, which showed that INH was
the most bactericidal drug and that RIF was less so. After the
first 2 days, the rate of killing in sputum slowed substantially, to
about log10 0.12 CFU/day. At this time the organisms are
thought to be persisters, and the predominant bactericidal
drug changed to RIF, while INH no longer appeared to con-
tribute to bactericidal activity. This again mirrors the relative
activities of RIF and INH in the stationary-phase culture.
Thus, the behavior of the log-phase culture reflects the activ-
ities of different drugs during the first 2 days of therapy, while
the behavior of the stationary-phase culture reflects the activ-
ities of different drugs during subsequent treatment.
We must now see whether population A or population B in
the stationary-phase culture most resembles the persisters
found in human lesions. There is substantial evidence that INH
has no bactericidal activity in regimens that start with four
drugs and that continue with RIF plus INH. We have already
mentioned the absence of any effect of INH in the first early
bactericidal activity study. Clinical trials also provide evidence.
Thus, in such regimens (conventionally referred to as 2SHRZ/
RIFINH [2 ethambutol-INH-RIF-pyrazinamide]) in eight
trials, relapses occurred in 5.2% of 1,225 patients infected with
initially sensitive strains and in 8.2% of 61 patients with initially
infected with resistant strains, which is a nonsignificant differ-
ence (9). In a recent trial (with a 2EHRZ/RIFINH [2 strep-
tomycin-INH-RIF-pyrazinamide] regimen) the corresponding
proportions were 3.7% of 190 patients and 4.0% of 23 patients,
respectively (6). In contrast to these findings with INH, bacte-
ricidal action throughout chemotherapy is due entirely to RIF,
together with pyrazinamide in the initial phase (9). This con-
tinuing action of RIF is also shown in its bactericidal action on
the stationary-phase culture throughout the 6-day period (Fig.
1C). While no assessment has yet been made of the gene
expression states of M. tuberculosis in sputum, the slow bacte-
ricidal activity of INH on population A and the complete
FIG. 4. Bactericidal activities of INH, RIF, and INH-RIF with
GAT1 and GAT2 against log-phase (A) and stationary-phase (B) cul-
tures of M. tuberculosis. See Fig. 1 for drug concentrations. H, INH; R,
RIF; HR, INH-RIF; HRG1, INH-RIF-GAT1; and HRG2, INH-RIF-
GAT2.
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absence of such activity on population B strongly suggest that
it is population B that resembles the lesional persisters. If this
is so, our findings show that addition of GAT does not appre-
ciably increase the sterilizing activity of INH or RIF, although
we have not been able to assess its activity against both drugs
together, nor have we been able to assess the activity of GAT
compared with those of regimens with pyrazinamide.
In summary, our results with GAT show that it has many of
the same features as INH, particularly strong bactericidal ac-
tivity against multiplying organisms but very limited sterilizing
activity against persisters. This suggests that, like INH, it would
be effective in retreatment regimens that do not contain RIF,
since in regimens without RIF, INH is a slowly sterilizing drug
(9). The concept is in agreement with assessments of retreat-
ment regimens in murine tuberculosis (1).
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